PDSB (PDS Biotechnology) Debt-to-Asset : 0.50 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PDSB PDS Biotechnology Corp PDSB
26 GF Score
Price $0.40
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology Debt-to-Asset?

PDS Biotechnology PDSB 26 Debt-to-Asset is 0.50 as of Jun. 2026. GuruFocus rates PDSB with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

PDS Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $4.35 Mil. PDS Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.01 Mil. PDS Biotechnology's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $8.81 Mil. PDS Biotechnology's debt to asset for the quarter that ended in Jun. 2026 was 0.50.

PDS Biotechnology  (NAS:PDSB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

PDS Biotechnology Debt-to-Asset Related Terms

PDS Biotechnology Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for PDS Biotechnology's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology Debt-to-Asset Chart

PDS Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.31 0.40 0.48 0.56

PDS Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.52 0.56 0.64 0.50

PDSB vs KPRX, ASBP, SNTI: Debt-to-Asset Comparison

For the Biotechnology subindustry, PDS Biotechnology's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PDS Biotechnology Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's Debt-to-Asset falls into.


PDSB
26GF Score
PDS Biotechnology Corp PDSB
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

PDS Biotechnology's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(5.167 + 11.759) / 30.494
=0.56

PDS Biotechnology's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4.354 + 0.009) / 8.807
=0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.50 mean?
PDS Biotechnology (PDSB) has a Debt-to-Asset of 0.50 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on PDS Biotechnology and its competitors.
Is PDS Biotechnology's Debt-to-Asset too high?
PDS Biotechnology's current Debt-to-Asset is 0.50. Overall, PDS Biotechnology has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's Debt-to-Asset compare to KPRX and ASBP?
PDS Biotechnology's Debt-to-Asset of 0.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on PDS Biotechnology and its competitors. PDS Biotechnology's current Debt-to-Asset is 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (PDSB) has a current Debt-to-Asset of 0.50. The current Debt-to-Asset is 0.50. PDS Biotechnology's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For PDS Biotechnology (PDSB), the current Debt-to-Asset is 0.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PDS Biotechnology Business Description

Other Exchanges EU6:Germany
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
26GF Score

Get the complete analysis for PDSB

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price